Dr. Charles Speakman Paxson is a Tacoma, Washington based male rheumatologist who is specialized in Rheumatology. Active license number of Dr. Charles Speakman Paxson for Rheumatology is 12940 in Washington. Dr. Charles Speakman Paxson treat joint disease similar to orthopedists but do not perform surgeries. He diagnose and treat diseases of joints, muscle, bones and tendons which includes arthritis, back pain, muscle strains, common athletic injuries and 'collagen' diseases.
Complete Profile:
Dr. Charles Speakman Paxson speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Rheumatology
Credentials:
M.D.
Gender:
Male
Practice Address:
9600 Veterans Dr Sw, Tacoma, Washington, 98493-5000
Phone:
253-582-8440
Fax:
253-589-4028
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1801998497
NPI Enumeration Date:
02 Sep, 2006
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Charles Speakman Paxson are as mentioned below.
License Number
Specialization
State
Status
12940
Rheumatologist
Washington
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
503 Alder Ave, Sumner, Washington
Zip:
98390-1323
Phone Number:
253-863-3912
Fax Number:
253-863-3912
Patients can reach Dr. Charles Speakman Paxson at 9600 Veterans Dr Sw, Tacoma, Washington or can call to book an appointment on 253-582-8440. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 March, 2024.